Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.56 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617566 | 0.87 | SFRP1 (0.62) | NAMPTSFRP1TBXAS1PDE4APDE4B | |
| SCHEMBL4619160 | 0.85 | SFRP1 (0.55) | NAMPTSFRP1TBXAS1TDP1 | |
| SCHEMBL4619417 | 0.84 | ALPL (0.54) | NAMPTTBXAS1 | |
| SCHEMBL4618242 | 0.82 | SFRP1 (0.58) | NAMPTSFRP1TBXAS1TDP1 | |
| SCHEMBL4616480 | 0.79 | SFRP1 (0.58) | NAMPTSFRP1TBXAS1TDP1 | |
| SCHEMBL4617818 | 0.79 | SFRP1 (0.58) | NAMPTSFRP1TBXAS1TDP1 | |
| SCHEMBL4619698 | 0.78 | NAMPT (0.49) | NAMPTSFRP1TBXAS1 | |
| SCHEMBL6101504 | 0.77 | ALDH1A1 (0.50) | NAMPTSFRP1TBXAS1 | |
| SCHEMBL27713238 | 0.77 | TDP1 (0.70) | TBXAS1TDP1 | |
| SCHEMBL4617287 | 0.76 | TBXAS1 (0.49) | NAMPTSFRP1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | NAMPT 3852/4885SFRP1 1/4885TBXAS1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.